Sentences with phrase «using liquid biopsy»

Examples will be given using liquid biopsy sample input from blood, cerebrospinal fluid, urine, and eye fluid.

«Tremendous advances have been made in DNA and RNA profiling in cells collected using a liquid biopsy.

He says that using a liquid biopsy test that was developed and now offered at Dana - Farber Cancer Institute, he was able to determine that the patient did indeed have the mutation, making her a good candidate for drugs that target it.

Not exact matches

Freenome, a liquid biopsy startup that's looking to enter clinical trials, is working on technology that would be able to detect cancer in the body, including its location and type, using only blood samples.

Liquid Biopsy Startup Freenome Using Recently Raised Funds to Show Clinical Validity, Utility

«A lot of times people underestimate the importance of the preanalytical stuff,» says Bramlett, advising that researchers should «think through all of that before you jump in, and make sure you have a good sample going into whatever technology you're going to use to evaluate your liquid biopsy.»

TruePrime LB addresses current liquid biopsy sensitivity and specificity issues by using adapted amplification of cancer - specific, large - fragment, cell - free DNA based on primer - free technology that combines the enzymes TthPrimPol and Phi29 DNA polymerase.

He explains that DNA - based liquid biopsies typically use standard blood collection tubes, and those based on polymerase chain reaction (PCR) are particularly easy for clinical laboratorians to understand and implement.

«Most of what we are all doing with liquid biopsies is dealing with very small numbers [of molecules], so using a poor sample extraction or nonoptimized kit can really get rid of a lot of the signal,» she says.

First, the research demonstrates that RB status can be tracked using cell - free DNA samples, an approach referred to as «liquid biopsy,» in prostate cancer patient samples.

Investigators compared DNA from the liquid blood biopsies to DNA tissue samples from the tumor, using mate - pair sequencing — an inexpensive whole exome sequencing that can reveal genetic changes that contribute to tumor growth.

In the next study, we plan to follow up using a blood - based liquid biopsy to determine in real - time the efficacy of the treatment,» said Professor John H. Lee, MD, Department of Cancer Research, Sanford Health, and Principal Investigator of the study.

The study, published in the journal Science Translational Medicine, is an important step towards use of «liquid biopsies» to revolutionise breast cancer care — by changing the way cancer is monitored in the clinic and informing treatment decisions.

«This will add a new dimension to research into «liquid biopsies» and facilitate the clinical use of extracellular vesicles to inform the physiology and health of organs that are hard to access, such as the placenta during human pregnancy,» said Yoel Sadovsky, director of the Magee - Womens Research Institute at the University of Pittsburgh.

We aim to build a novel liquid biopsy platform for the cases with a low burden in plasma using a sensitive whole genome, whole methylome and epigenetics analyses.

The P4 medicine concept is fully realised in the context of Liquid Biopsy, since the patient's blood is used as a biomarker for the prognosis and diagnosis of the disease status.

Scientific theme The theme for the July workshop is liquid biopsy: the potential of molecular markers in the blood or other bodily fluids to be used to detect disease state.

All these liquid biopsy samples could be used in different diagnostic fields, which will be addressed in this presentation.

«There has been a lot of interest in using so called liquid biopsies as a relatively non-invasive way to detect cancer.

A minimally invasive alternative to invasive tissue biopsy is the use of liquid biopsy, which analyzes ctDNA or CTCs in a liquid biological sample (i.e. urine, blood, or serum).

DENVER — Three manuscripts published in the recent issue of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC), explored the versatility of liquid biopsies by identifying EGFR mutations using circulating tumor DNA (ctDNA) in urine and plasma and examining circulating tumor cells (CTCs) in plasma to predict the risk of lung cancer recurrence after surgical resection.

«It also uses peripheral blood and therefore could potentially act as a liquid biopsy if it were validated for clinical use.»

«In the long - term, there is the possibility that this type of liquid biopsy method could be used for screening,» he said.

Exposure was confirmed by isolation of moxidectin from a biopsy specimen of adipose tissue, using liquid chromatography - mass spectroscopy methods.